HIV/AIDS
Research from the United States and France in HIV/AIDS provides new insights
Published in AIDS Weekly, June 5th, 2006
Study 1: HAART protects against initial and subsequent AIDS-defining illnesses.
Scientists writing in the American Journal of Epidemiology report, "The effect of highly active antiretroviral therapy (HAART) on multiple acquired immunodeficiency syndrome (AIDS)-defining illnesses remains unclear. Between 1984 and 2005, 573 male human immunodeficiency virus seroconverters in four US urban centers were followed for a median of 9.7 years. During follow-up, 345, 113, 50, and 65 men incurred 0, 1, 2, and >2 AIDS-defining illnesses, respectively."
...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
Source: AIDS Weekly (2006-06-05)
More Articles from AIDS Weekly
- HIV/AIDS Lipoatrophy
HAART-associated facial lipoatrophy corrected by polylactic acid implants - HIV/AIDS Prognosis
Higher set point HIV-1 RNA and more-severe acute illness predict mortality - HIV/AIDS-Related Kaposi Sarcoma
Kaposi sarcoma remission associated with HIV suppression and is independent of PI therapy - Business Update
Constella Group convenes advisory board led by Tommy G. Thompson - Business Update
Female Health Company receives initial order from Indian government for female condoms - Collaborations
Bristol-Myers Squibb, Gilead submit NDA for Sustiva, Truvada for HIV treatment - More from this issue of AIDS Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
